Oncolytic viruses for cancer therapy I. Cell-external factors: virus entry and receptor interaction.

Published

Journal Article (Review)

After being recognized for their anti-neoplastic properties at the beginning of the last century, viruses are again being considered for use as therapeutic agents against cancer. Certain virus species have a propensity to replicate within transformed cells, which are commonly rendered vulnerable due to tumor-specific defects in their defense against viral infection. Other viruses have been modified to subject them to tumor-specific growth conditions. Oncolytic viruses carry the promise to efficiently target cancer cells for destruction and spread throughout tumor tissue to reach distant neoplastic loci without causing collateral damage to healthy tissues. In contrast to conventional cancer chemotherapy, viral anti-neoplastic agents require complex interactions with the host organism to reach their target and to unfold their oncolytic activity. Recent progress in the elucidation of the molecular mechanisms of viral pathogenesis has opened up new opportunities to manipulate virus-host interactions, generating effective anti-tumor strategies. On the other hand, significant obstacles towards the application of safe and efficacious viral therapies have become apparent. These frequently relate to the lack of cell culture and animal tumor models that accurately reflect the characteristics of cancerous tissues in patients. Throughout the past century, viral therapeutics against cancer have evolved into a new class of treatment strategies characterized by unique opportunities and challenges. A growing number of oncolytic viruses has entered clinical investigation or is scheduled to do so in the near future. Great efforts are being undertaken to rekindle an old idea and, with the help of new technologies, to realize its promise of new treatment facilities for cancer.

Full Text

Duke Authors

Cited Authors

  • Campbell, SA; Gromeier, M

Published Date

  • March 2005

Published In

Volume / Issue

  • 28 / 3

Start / End Page

  • 144 - 149

PubMed ID

  • 15772465

Pubmed Central ID

  • 15772465

International Standard Serial Number (ISSN)

  • 0378-584X

Digital Object Identifier (DOI)

  • 10.1159/000083659

Language

  • eng

Conference Location

  • Switzerland